Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of zampilimab in idiopathic pulmonary fibrosis
NL-OMON61098Phase 2Not yet recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Zampilimab in idiopathic pulmonary fibrosis (IPF), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline in percent predicted forced vital capacity. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Zampilimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON61098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61098.